For research and education only · Not reviewed by a medical professional · Disclaimer

← PepsRadar home

Research field guide

Melanotan I vs Melanotan II: one became a medicine, one did not

Content updated · how dates work

Melanotan I and Melanotan II were developed in the same lab to darken skin, but only Melanotan I (afamelanotide) became an approved medicine, for a rare light-sensitivity disease. Melanotan II has only tiny early studies and documented safety concerns.

PepsRadar editorial · October 5, 2026 · Original, AI-assisted guide · Not reviewed by a medical professional

01

Same starting point, different paths

Both compounds are synthetic versions of alpha-melanocyte-stimulating hormone, the body's signal for producing pigment. Melanotan I was later developed as afamelanotide. Melanotan II is a smaller ring-shaped molecule that acts on more melanocortin receptors, including ones involved in appetite and sexual function, which helps explain its broader side effects.

Source: Afamelanotide for Erythropoietic Protoporphyria. ↗

Source: Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. ↗

02

Melanotan I: tested and approved for one rare disease

Afamelanotide was tested in randomized trials in erythropoietic protoporphyria (EPP), a rare condition in which sunlight causes severe pain. In two trials published in 2015, people given afamelanotide implants could spend longer in sunlight without pain, and quality-of-life measures improved.

It is approved in the U.S. as Scenesse, an implant placed by trained clinicians for adults with EPP. Its label includes skin-surveillance and pigment-change precautions. The approval covers that implant for that disease, not tanning or research vials.

Source: Afamelanotide for Erythropoietic Protoporphyria. ↗

Source: dailymed.nlm.nih.gov ↗

03

Melanotan II: a tiny pilot and a safety warning

The first human study of Melanotan II was a 1996 pilot phase 1 trial with three participants. Pigmentation increased in some of them, and nausea, drowsiness and prolonged unwanted erections were reported. Two small trials in 1998 and 2000 later tested it for erectile dysfunction in 20 men; it was never developed further.

FDA's page on compounding substances that may present significant safety risks notes serious adverse-event reports for Melanotan II, including melanoma, a brain-swelling syndrome and priapism. Its compounding nomination was withdrawn, and it is on the agenda for FDA's compounding advisory committee before the end of February 2027. It is not approved for any use. PepsRadar does not list Melanotan II products or link to sellers for it.

Source: Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. ↗

Source: doi.org ↗

Source: fda.gov ↗

Source: fda.gov ↗

04

Where bremelanotide (PT-141) fits

Bremelanotide, also called PT-141, is a related melanocortin drug developed from the same line of research. It is approved in the U.S. as Vyleesi for a specific sexual-desire disorder in premenopausal women, based on two randomized trials. It is a separate medicine with its own label, not a form of Melanotan II.

Source: Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. ↗

Source: medlineplus.gov ↗

Continue with the original research

Study examples are based on selected publication abstracts and the explicitly described source documents. This is not a systematic review or an individualized treatment guide. Editorial scope and methods.

See something wrong on this page? Report a mistake · Corrections